A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Exclusion Criteria

• •1. Subjects who required systemic corticosteroids or antibiotics or hospitalized due to poorly controlled COPD or who had lower respiratory tract infections that required antibiotics within 4 weeks prior to Screening to pre-randomization;
• •2. Subjects who had respiratory tract infections that required antibiotics within 2 weeks prior to Screening to pre-randomization;
• •3. Subjects with other respiratory or respiratory related diseases, including but not limited to asthma, active tuberculosis, lung cancer, interstitial pulmonary disease, α1-antitrypsin deficiency, pulmonary heart disease, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease;
• •4. Subjects with lung volume reduction surgery within the 12 months prior to Screening;
• •5. Subjects who have Other known serious medical conditions；
• •6. Subjects receiving oxygen therapy required for greater than 15 hours a day;
• •7. Clinically significant electrocardiogram abnormality；
• •8. Subjects with significant laboratory abnormality at screening；
• •9. Suspected allergy to any ingredient in the study drug;
• •10. Participation in clinical trials of any drug or medical device (except for screening failures) within 4 weeks before screening, or within 5 half-lives of the drug at screening (whichever is longer);
• •11. Pregnant or lactating females;
• •12. History of drug abuse within one year before screening
• •13. Other conditions judged by the investigator to be not suitable to participate in the trial.